7Van Belle SJ, Cocquyt V. Fasaprepitant dimeglumine (MK-O517 or L-785,298), an intravenous neurokinin-1 antagonist for the preven- tion of chemotherapy induced nausea and vomiting [ J ]. Expert Opin Pharmacother,2008,9( 18 ) :3261-3270.
8Saito H,Yoshizawa H,Yoshimori K,et al. Efficacy and safety of sin- gle-dose fosaprepitant in the prevention of chemotherapy-induced nau- sea and vomiting in patients receiving high-dose cisplatin: a multicen- tre, randomised, double-blind, placebo-controlled phase 3 trial [ J ]. Ann Onco1,2013,24 (4) : 1067-1073.
9Grunberg S, Chua D, Maru A, et al. Single-dose fosaprepitant for the prevention of chemotherapy-induced nausea and vomiting associated with cisplatin therapy: randomized, double-blind study protocol-- EASE[J]. J Clin Oncol,20!1,29( 11 ) :1495-1501.
10Ando Y, Hayashi T, Ito K, et al. Comparison between 5-day aprepi- tant and single-dose fosaprepitant meglumine for preventing nausea and vomiting induced b.y cisplatin-based chemotherapy [ J ]. Support Care Cancer,2015, [ Epub ahead of print].
